A Placebo-Controlled Study of Intranasal Sumatriptan for the Acute Treatment of Migraine

Authors:
  • PHP.P.A. Humphrey
    P.P.A. Humphrey
  • WFW. Feniuk
    W. Feniuk
  • AMA.S. Marriott
    A.S. Marriott
  • RTR.J.N. Tanner
    R.J.N. Tanner
  • MJM.R. Jackson
    M.R. Jackson
  • MTM.L. Tucker
    M.L. Tucker
  • EBE.G. Brown
    E.G. Brown
  • CEC.A. Endersby
    C.A. Endersby
  • SMSmith
    Smith
  • JTJ.C.C Talbot
    J.C.C Talbot
  • JLJ.W. Lance
    J.W. Lance
  • VPV. Pfaffenrath
    V. Pfaffenrath
Publisher website
Google Scholar
Abstract
A double-blind, randomized, multicentre, parallel-group study was carried out to compare intranasal sumatriptan with placebo in the treatment of migraine. Seventy-four patients (37 in each treatment group) were recruited into the study. Patients received two insufflations of the same treatment (sumatriptan or placebo) 15 min apart. Sumatriptan (20 mg plus 20 mg) was more effective than placebo at relieving headache, defined as a reduction in severity from moderate (grade 2) or severe (grade 3) to mild (grade 1) or none (grade 0), at 60 and 120 min. At 120 min, 75% of patients in the sumatriptan group reported headache relief, compared with 32% of patients in the placebo group (p < 0.001); 53% of patients in the sumatriptan group were completely pain-free, compared with 11 % in the placebo group. A clinically significant reduction in the incidence of nausea, vomiting and photophobia was observed in the sumatriptan group compared with the placebo group, and sumatriptan was also more effective at reducing the functional disability of the patients. A similar number of patients reported migraine recurrence, within 24 h in both treatment groups. The observed reduction in headache severity, functional disability and nausea following intranasal administration of sumatriptan would appear to obviate the need for a concomitant anti-emetic during a migraine attack. The results support the further development and testing of intranasal sumatriptan.